San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.
Recardio Inc. today announced that it has successfully completed a Phase 1 single and multiple ascending dose clinical study with dutogliptin. This study enrolled 45 healthy humans at a single site in Vienna, Austria with AGES approval under a US IND.
“The Phase 1 single and multiple ascending dose study with dutogliptin confirmed the drug’s safety and established an understanding of the subcutaneous pharmacokinetic and pharmacodynamic properties, enabling us to select the dose for Phase 2.” said Darrell Nix, Chief Scientific Officer of Recardio.
Recardio is now initiating a global, randomized, double-blind, placebo-controlled, safety and efficacy Phase 2 Study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
“Opening an IND and completion of the Phase 1 study represent important milestones in our efforts to bring this important treatment to patients with acute myocardial infarction.” said Roman Schenk, Executive Chairman of Recardio. “This Phase 1 study is also the foundation for our development of a therapeutic platform with dutogliptin as a regenerative medication for patients with a range of cardiovascular diseases.”
More information about the clinical program is available by visiting the following link.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: https://recardio.eu/